Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Acetaminophen | Abenol | APAP | ||
| Dexamethasone | Adexone | Desametasone | ||
| Diphenhydramine | Aleryl | |||
| Flotetuzumab | MGD006|S80880 | CD123 (IL3RA) Antibody 14 | Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 (IL32A) and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488). | |
| Ranitidine | Alquen | Ranitidine HCL |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04681105 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Flotetuzumab + Ranitidine Dexamethasone + Diphenhydramine + Flotetuzumab + Ibuprofen + Ranitidine | Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Active, not recruiting | USA | 0 |